|
1
|
Liu N, Zhou H, Yang G, Geng C, Jian Y, Guo
H and Chen W: Retrospective analysis of genetic abnormalities and
survival in 131 patients with multiple myeloma. Oncol Lett.
9:930–936. 2015.PubMed/NCBI
|
|
2
|
Tan E, Weiss BM, Mena E, Korde N, Choyke
PL and Landgren O: Current and future imaging modalities for
multiple myeloma and its precursor states. Leuk Lymphoma.
52:1630–1640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang F, Zhang W, Guo L, Bao W, Jin N, Liu
R, Liu P, Wang Y, Guo Q and Chen B: Gambogic acid suppresses
hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial
growth factor expression via inhibiting phosphatidylinositol
3-kinase/Akt/mammalian target protein of rapamycin pathway in
multiple myeloma cells. Cancer Sci. 105:1063–1070. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng M, Wang J, Chen Y, Zhang L and Liu D:
Combination of SF1126 and gefitinib induces apoptosis of
triple-negative breast cancer cells through the PI3K/AKT-mTOR
pathway. Anticancer Drugs. 26:422–427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang H, Bajraszewski N, Wu E, Wang H,
Moseman AP, Dabora SL, Griffin JD and Kwiatkowski DJ: PDGFRs are
critical for PI3K/Akt activation and negatively regulated by mTOR.
J Clin Invest. 117:730–738. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Padhye S, Dandawate P, Yusufi M, Ahmad A
and Sarkar FH: Perspectives on medicinal properties of plumbagin
and its analogs. Med Res Rev. 32:1131–1158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang T, Wu F, Jin Z, Zhai Z, Wang Y, Tu B,
Yan W and Tang T: Plumbagin inhibits LPS-induced inflammation
through the inactivation of the nuclear factor-kappa B and mitogen
activated protein kinase signaling pathways in RAW 264.7 cells.
Food Chem Toxicol. 64:177–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inbaraj JJ and Chignell CF: Cytotoxic
action of juglone and plumbagin: A mechanistic study using HaCaT
keratinocytes. Chem Res Toxicol. 17:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saowakon N, Lorsuwannarat N, Changklungmoa
N, Wanichanon C and Sobhon P: Paramphistomum cervi: The in vitro
effect of plumbagin on motility, survival and tegument structure.
Exp Parasitol. 133:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shieh JM, Chiang TA, Chang WT, Chao CH,
Lee YC, Huang GY, Shih YX and Shih YW: Plumbagin inhibits
TPA-induced MMP-2 and u-PA expressions by reducing binding
activities of NF-kappaB and AP-1 via ERK signaling pathway in A549
human lung cancer cells. Mol Cell Biochem. 335:181–193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He
ZX, Zhang X, Wang D, Yang YX, Yang T, et al: Plumbagin induces cell
cycle arrest and autophagy and suppresses epithelial to mesenchymal
transition involving PI3K/Akt/mTOR-mediated pathway in human
pancreatic cancer cells. Drug Des Devel Ther. 9:537–560.
2015.PubMed/NCBI
|
|
12
|
Troeltzsch M, Oduncu F, Mayr D, Ehrenfeld
M, Pautke C and Otto S: Root resorption caused by jaw infiltration
of multiple myeloma: Report of a case and literature review. J
Endod. 40:1260–1264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Que W, Li S and Chen J: NS-398 enhances
the efficacy of bortezomib against RPMI8226 human multiple myeloma
cells. Mol Med Rep. 7:1641–1645. 2013.PubMed/NCBI
|
|
14
|
Nakazato T, Sagawa M and Kizaki M:
Triptolide induces apoptotic cell death of multiple myeloma cells
via transcriptional repression of Mcl-1. Int J Oncol. 44:1131–1138.
2014.PubMed/NCBI
|
|
15
|
Ono T, Ota A, Ito K, Nakaoka T, Karnan S,
Konishi H, Furuhashi A, Hayashi T, Yamada Y, Hosokawa Y and Kazaoka
Y: Plumbagin suppresses tumor cell growth in oral squamous cell
carcinoma cell lines. Oral Dis. 21:501–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eldhose B, Gunawan M, Rahman M, Latha MS
and Notario V: Plumbagin reduces human colon cancer cell survival
by inducing cell cycle arrest and mitochondria-mediated apoptosis.
Int J Oncol. 45:1913–1920. 2014.PubMed/NCBI
|
|
17
|
Dandawate P, Ahmad A, Deshpande J, Swamy
KV, Khan EM, Khetmalas M, Padhye S and Sarkar F: Anticancer
phytochemical analogs 37: Synthesis, characterization, molecular
docking and cytotoxicity of novel plumbagin hydrazones against
breast cancer cells. Bioorg Med Chem Lett. 24:2900–2904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuchs O: Targeting of NF-kappaB signaling
pathway, other signaling pathways and epigenetics in therapy of
multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 13:16–34.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li YC, He SM, He ZX, Li M, Yang Y, Pang
JX, Zhang X, Chow K, Zhou Q, Duan W, et al: Plumbagin induces
apoptotic and autophagic cell death through inhibition of the
PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.
Cancer Lett. 344:239–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koldehoff M, Beelen DW and Elmaagacli AH:
Inhibition of mTOR with everolimus and silencing by vascular
endothelial cell growth factor-specific siRNA induces synergistic
antitumor activity in multiple myeloma cells. Cancer Gene Ther.
21:275–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gay F, Oliva S, Petrucci MT, Conticello C,
Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L,
Carella A, et al: Chemotherapy plus lenalidomide versus autologous
transplantation, followed by lenalidomide plus prednisone versus
lenalidomide maintenance, in patients with multiple myeloma: a
randomised, multicentre, phase 3 trial. Lancet Oncol. 16:1617–1629.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Y, Zhou X, Xiao M, Hong Z, Gong Q,
Jiang L and Zhou J: Discovery of chrysoeriol, a PI3K-AKT-mTOR
pathway inhibitor with potent antitumor activity against human
multiple myeloma cells in vitro. J Huazhong Univ Sci Technolog Med
Sci. 30:734–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong M, Yang G, Liu H, Liu X, Lin S, Sun D
and Wang Y: Aged black garlic extract inhibits HT29 colon cancer
cell growth via the PI3K/Akt signaling pathway. Biomed Rep.
2:250–254. 2014.PubMed/NCBI
|
|
24
|
Chen X, Yang C, Xu Y, Zhou H, Liu H and
Qian W: The microtubule depolymerizing agent CYT997 effectively
kills acute myeloid leukemia cells via activation of caspases and
inhibition of PI3K/Akt/mTOR pathway proteins. Exp Ther Med.
6:299–304. 2013.PubMed/NCBI
|
|
25
|
Jang J, Jeong SJ, Kwon HY, Jung JH, Sohn
EJ, Lee HJ, Kim JH and Kim SH, Kim JH and Kim SH: Decursin and
doxorubicin are in synergy for the induction of apoptosis via STAT3
and/or mTOR pathways in human multiple myeloma cells. Evid Based
Complement Alternat Med. 2013:5063242013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen MB, Zhang Y, Wei MX, Shen W, Wu XY,
Yao C and Lu PH: Activation of AMP-activated protein kinase (AMPK)
mediates plumbagin-induced apoptosis and growth inhibition in
cultured human colon cancer cells. Cell Signal. 25:1993–2002. 2013.
View Article : Google Scholar : PubMed/NCBI
|
